Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma

NCT01556035 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)

Interventions

DRUG: Lenalidomide

Sponsor

University Hospital, Bordeaux